AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Recent advances in multiple myeloma (MM) therapy have substantially improved patient outcomes; however, MM remains incurable and is frequently accompanied by profound immune dysfunction and anemia, and the mechanisms linking tumor-driven immune suppression with defective hematopoiesis remain poorly understood. Here, we identify tumor-derived leukocyte immunoglobulin-like receptor B4 (LILRB4) as a master regulator of inflammatory hematopoietic reprogramming that couples immune evasion with anemia and define its therapeutic potential.
We performed single-cell RNA sequencing of bone marrow mononuclear cells from 12 newly diagnosed MM patients and used consensus non-negative matrix factorization to define malignant plasma-cell states, with clinical validation in the CoMMpass cohort. Flow cytometry identified an erythroid–myeloid hybrid population termed erythroid differentiation-defective myeloid cells (EDMCs), characterized as CD45?CD235a?CD71?CD11b?CD33?HLA-DR? in patients and CD45?Ter119?CD71?CD11b?Gr1? in murine models. Immunocompetent Vk*MYC and 5T33 MM models were used to evaluate immune and hematopoietic remodeling, while integrated ATAC-seq, proteomic, phosphoproteomic, ChIP-qPCR, and signaling analyses defined downstream mechanisms. The therapeutic activities of PROTAC-mediated LILRB4 degradation and LILRB4 CAR-T cells were further evaluated in xenograft models and patient-derived co-culture systems.
Single-cell profiling identified an LILRB4-high inflammatory malignant plasma-cell state associated with early mortality, an increased abundance of exhausted CD8? T cells, and inferior progression-free survival. In primary MM samples, tumor-cell LILRB4 expression inversely correlated with hemoglobin levels (r = −0.7211) and positively correlated with EDMC abundance (r = 0.6762), while EDMC frequency inversely correlated with hemoglobin levels (r = −0.4035). EDMCs exhibited potent immunosuppressive activity and suppressed IFN-γ production by CD8? T cells to an extent comparable to that of myeloid-derived suppressor cells (MDSCs). Conditioned medium from LILRB4-overexpressing myeloma cells promoted the conversion of erythroid progenitors into EDMCs. Consistently, LILRB4 overexpression in vivo accelerated myeloma progression, aggravated anemia, expanded EDMC populations, and impaired antitumor T-cell responses.
Mechanistically, LILRB4 activated the Src-family kinase/SHP2-dependent ERK-AP-1 signaling cascade, remodeled inflammatory chromatin accessibility, and induced the secretion of CCL3 and GM-CSF. These tumor-derived inflammatory factors redirected erythroid progenitors toward an immunosuppressive myeloid-like fate, with CCL3 driving mTORC1-dependent hematopoietic reprogramming and EDMC expansion. Genetic or pharmacologic disruption of this pathway through CCL3 deletion, mTORC1 inhibition, or PROTAC-mediated LILRB4 degradation restored erythropoietic homeostasis and enhanced antitumor immunity. Furthermore, LILRB4 CAR-T cells demonstrated potent cytotoxicity and cytokine production against LILRB4? myeloma cells and reduced tumor burden in xenograft models, showing efficacy comparable to that of BCMA CAR-T cells.
These findings reveal an unrecognized mechanism of inflammatory hematopoietic reprogramming in which tumor-derived LILRB4 couples immune suppression with anemia by redirecting erythroid differentiation toward immunosuppressive EDMCs through the LILRB4–CCL3–mTORC1 axis. Targeting this pathway simultaneously restores immune surveillance and hematopoietic balance, highlighting LILRB4 as a therapeutic vulnerability in MM. LILRB4-directed PROTAC degradation and CAR-T-cell therapy represent promising pharmacologic and cellular strategies for overcoming disease progression and alleviating anemia.
Funding support: Noncommunicable Chronic Diseases-National Science and Technology Major Project #2023ZD0501300; Key International Cooperation Projects of Tianjin #25YFGKHZ00100; Key Projects of Tianjin Natural Science Foundation #25JCZDJC00530.
DISCLOSURES
Huaqing Jing, PhD: No relevant conflicts of interest to declare.